Forward Event Stocks

[babycakes]

MTSX....3.91 (bid/ask aftermarket on weekend) Spring 05
Metal Storm Enters Agreement with Lockheed Martin for Torpedo Defense Project
TUESDAY, OCTOBER 19, 2004 9:52 AM
- BusinessWire

MTSX
3.911 -0.049 News


Enter Symbol:


Enter Keyword:



ARLINGTON, Va., Oct 19, 2004 (BUSINESS WIRE) -- International ballistics company Metal Storm Limited (NASDAQ:MTSX and ASX:MST) today announced that it has entered into an agreement with Lockheed Martin (LMT) to conduct studies and technical demonstrations in order to establish the feasibility of the Metal Storm torpedo defense system over a four-month evaluation period. Terms of the agreement were not disclosed.

"This agreement is an important step forward in the advancement of our technology," said Metal Storm Limited's Chief Executive Officer Charles Vehlow. "Once we have completed the four-month evaluation of the design and concept, we hope to begin early prototype development. We are encouraged by the growing receptivity we have received from Lockheed Martin and other defense and military organizations."

"The Lockheed Martin approach to defeating torpedoes for both surface and subsurface combatants, coupled with Metal Storm's launch capability, offers an exciting opportunity to demonstrate the feasibility of our combined technologies for the benefit of naval personnel worldwide," said Dr. Joseph R. Mayersak, Advanced Projects general manager at Lockheed Martin Missiles and Fire Control in Manassas, VA. "Lockheed Martin is pleased to be working with Metal Storm on this special project for the U.S. Navy."

About Metal Storm

Metal Storm Limited is a defense technology company engaged in the development of electronically initiated ballistics systems using its unique "stacked round" technology. The company is headquartered in Brisbane, Australia and incorporated in the US, with offices in Washington DC and a defence engineering capability located in Seattle, operating as ProCam Machine LLC. The company has invented a ballistics technology that has no known conventional equivalent. Metal Storm is working with government agencies and departments, as well as industry, to develop a variety of systems utilising the Metal Storm non-mechanical, electronically fired stacked ammunition system.

About Lockheed Martin

Lockheed Martin, headquartered in Bethesda, Maryland, employs about 130,000 people worldwide and is principally engaged in the research, design, development, manufacture, and integration of advanced technology systems, products, and services. The company reported 2003 sales of $31.8 billion. More information about the company is available on the Internet at www.lockheedmartin.com.

Safe Harbour

Certain statements made herein that use the words "estimate", "project", "intend", "expect", "believe" and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements of the company to be materially different from those which may be expressed or implied by such statements, including, among others, risks or uncertainties associated with the development of the company's technology, the ability of the company to meet its financial requirements, the ability of the company to protect its proprietary technology, potential limitations on the company's technology, the market for the company's products, government regulation in Australia and the US, changes in tax and other laws, changes in competition and the loss of key personnel. For additional information regarding these and other risks and uncertainties associated with the company's business, reference is made to the company's reports filed from time to time with the Securities and Exchange Commission, including the company's Form 20-F.

SOURCE: Metal Storm Limited

Metal Storm, Inc.
Charles Vehlow, 703-248-8218
[e-mail]
[e-mail]
or
Investors:
Lippert Heilshorn & Assoc
Jody Burfening/David Waldman, 212-838-3777
[e-mail]
or
Media:
Lippert Heilshorn & Assoc
Chenoa Taitt, 212-838-3777
[e-mail]

[lman]

Thanks,nice board, marked eom

[poolplayer]

Great idea Ed! Board marked and I'll be back with some DD for posting.

[originunknown]

Great Board Edf! Consider it BMed and I also added it to the OTC iBox.

[bagheera]

NEOP..53
DUBLIN, Ohio--(BUSINESS WIRE)--Dec. 14, 2004--
Neoprobe Corporation (OTCBB:NEOP), a diversified
developer of innovative oncology and cardiovascular surgical and
diagnostic products, today announced that it raised $8.1 million
through the issuance of $8 million and $100,000 in four-year,
convertible promissory notes to funds of Great Point Partners, LLC and
David C. Bupp (Neoprobe's President and CEO), respectively. The notes
will bear interest at 8% per annum and are freely convertible into
shares of the company's common stock at a price of $0.40 per share.
The conversion price represents the 10-day volume weighted average
trading price of the company's common stock through December 10, 2004.
As part of this transaction, Neoprobe issued five-year warrants to the
investors to purchase 10,125,000 shares of the Company's common stock
at an exercise price of $0.46. The Company may force conversion of the
note prior to its stated maturity under certain circumstances.
Specific details of this transaction may be found in the Company's
Form 8-K to be filed with the Securities and Exchange Commission on or
about December 16, 2004. Proceeds from the note will be used primarily
to fund late-stage clinical development of the Company's most advanced
radiopharmaceutical agent, Lymphoseek(TM), for the assessment of the
spread of breast cancer and melanoma to the lymphatic system and to
complete the commercial launch of the company's blood flow measurement
products, the Quantix/OR(TM) and the Quantix/ND(TM).
David Kroin, Managing Director of Great Point Partners, LLC,
stated, "We are excited to provide this growth financing for Neoprobe
and believe the Company is a uniquely positioned, diversified
biomedical company. The existing gamma device business has tremendous
brand value as evidenced by its continuing profit stream and we expect
that to be enhanced with the blood flow products launch in 2005. In
addition, Lymphoseek and RIGScan(R) have the potential to unlock
significant upside for shareholders. We look forward to working with
and supporting the Neoprobe management team as they execute their
business strategy."
David Bupp commented, "We are very pleased to have an investor of
Great Point's stature become involved with Neoprobe Corporation. The
completion of this financing will provide Neoprobe with the capital
resources to move forward with the clinical development of Lymphoseek
and to execute the commercial introduction of the Quantix products
early next year. In addition, the financing will allow Neoprobe to
devote other resources to prepare for the anticipated commencement of
clinical evaluation activities for RIGScan CR in 2005."

About Neoprobe

Neoprobe develops and provides innovative surgical and diagnostic
products that enhance patient care by meeting the critical decision
making needs of healthcare professionals. Neoprobe currently markets
the neo2000(R) line of gamma detection systems that are widely used by
cancer surgeons for intraoperative lymphatic mapping. Neoprobe is also
in the process of commercializing the Quantix(R) line of blood flow
measurement products developed by its subsidiary, Cardiosonix Ltd.,
that are designed to be used by cardiovascular surgeons, neurosurgeons
and critical care physicians. In addition, Neoprobe holds significant
interests in the development of related biomedical systems and agents
including Lymphoseek(TM) and RIGScan(R) CR. Lymphoseek is an
investigational drug being developed as a lymphatic tracing agent in
conjunction with the University of California, San Diego. The RIGS(R)
system is an investigational technology that combines the Company's
gamma detection device technology with a proprietary disease-specific
radiolabeled cancer targeting agent, and a patented surgical method to
get real-time information to locate tumor deposits that may not be
detectable by conventional methods. Before surgery, a cancer patient
is injected with one of the targeting agents, which circulates
throughout the patient's body and binds specifically to cancer cell
antigens or receptors. Concentrations of the targeting agent are then
located during surgery by the company's gamma-detection instrument,
which emits an audible tone to direct the surgeon to targeted tissue.
The Company's strategy is to deliver superior growth and shareholder
return by maximizing its strong position in gamma detection
technologies and diversifying into new, synergistic biomedical markets
through continued investment and selective acquisitions.

About Great Point LLC

Great Point Partners LLC of Greenwich, Connecticut manages the
Biomedical Value Fund, L.P., a bottoms-up, primary research oriented,
investment fund formed to invest principally in undervalued publicly
traded life sciences, medical technology and other healthcare
companies by purchasing securities in the open market, financing
growth companies through PIPE (Private Investment in Public Equity)
financings, and in other directly negotiated transactions.

Statements in this news release, which relate to other than
strictly historical facts, such as statements about the Company's
plans and strategies, expectations for future financial performance,
new and existing products and technologies, and markets for the
Company's products, are forward-looking statements. The words
"believe," "expect," "anticipate," "estimate," "project," and similar
expressions identify forward-looking statements that speak only as of
the date hereof. Investors are cautioned that such statements involve
risks and uncertainties that could cause actual results to differ
materially from historical or anticipated results due to many factors
including, but not limited to, the Company's continuing operating
losses, uncertainty of market acceptance of its product, reliance on
third party manufacturers, accumulated deficit, future capital needs,
uncertainty of capital funding, dependence on limited product line and
distribution channels, competition, limited marketing and
manufacturing experience, risks of development of new products,
regulatory risks and other risks detailed in the Company's most recent
Annual Report on Form 10-KSB and other Securities and Exchange
Commission filings. The Company undertakes no obligation to publicly
update or revise any forward-looking statements.



KEYWORD: NORTH AMERICA OHIO UNITED STATES
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY HOSPITALS MEDICAL DEVICES PHARMACEUTICAL
SOURCE: Neoprobe Corporation

[EdF]

MYMX .21/.23 Third Quarter 2005
see note below

Mymetics Receives NIH Approval to Advance HIV Vaccine Into Late Preclinical Studies
Friday December 17, 12:25 pm ET

NYON, Switzerland, Dec. 17 /PRNewswire-FirstCall/ -- Mymetics Corporation (OTC Bulletin Board: MYMX - News) announced today that it has received approval from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to begin advanced preclinical testing of the Company's trimeric gp41 vaccine in nonhuman primates. The study will run through the end of the third quarter of 2005, testing the second generation of HIV vaccines in development. Based on the results of the NIH-approved study, Mymetics expects to initiate advanced toxicology testing by the end of 2005 in preparation for filing an Investigational New Drug (IND) application in 2006.

Dr. Sylvain Fleury, Chief Scientific Officer of Mymetics, commented, "We are greatly pleased to have received our first formal recognition from the NIH for our program in HIV vaccinology. We have had strong results in this program to date, including neutralizing antibodies capable of blocking transcytosis and primary T cell and macrophage infections by primary HIV isolates. Our goal with the NIH-approved study is to further examine the potential of our gp41 vaccine approach and to gain additional data, including immunogenicity and stability, relevant to advancing our next-generation product."

Mymetics' Chief Executive Officer, Christian J.-F. Rochet, stated, "The NIAID-approved studies will place us among a small group of research teams poised to enter the clinic with a promising vaccine candidate. As we have previously announced, we anticipate signing in 2005 a partnership agreement with a major health sciences company to assist us in human clinical trials, for which we plan to file by 2006, pending the results of our preclinical program."

Mymetics' HIV Vaccine Program

In 2003, Mymetics created its first-generation trimeric gp41 HIV vaccine candidate. The Company is now developing next-generation vaccines that contain a more complete sequence of the wild-type gp41, including key neutralizing epitopes. A primary objective in the Company's vaccine design program is to impair the molecular mimicry between gp41 and the IL-2 cytokine (Interleukin-2) of the infected host. Mymetics' researchers discovered this mimicry in 1997 and believe that it is a major reason underlying the shutting down of the immune system seen in patients with HIV and AIDS.

Mymetics Corporation is a biotechnology company focused on the development of human and animal vaccines and therapies in the field of retroviral and viral autoimmune diseases, including HIV-1 infection. The Company's key discovery is a fundamental though subtle three-dimensional mimicry between the viral envelope glycoprotein gp41 of HIV-1 and the IL-2 cytokine (Interleukin-2) of the infected host. Based on this understanding of molecular mimicry, Mymetics has been able to engineer gp41 proteins capable of eliciting neutralizing antibodies against primary HIV-1 strains and has also designed specific therapeutic molecules which have the potential to prevent and/or delay the disease. Mymetics' platform technology can also be applied to other retrovirus-related diseases that involve similar mimicries, including certain oncoviruses often associated with human leukemia. For more information, please visit Mymetics' Web site at http://www.mymetics.com .

NOTE: On 12/07 they filed a SB2 for 89 million. This is a good example of a backburner play as the PPS may fall considerably as the SB2 works it way through the system. By 3Q 2005, this may be a much cheaper play as we anticipate the completion of the preclinical trials and the possible partnership with a "major health sciences company."

[sublime]

great idea, ed! boardmarked :)

[Capt_Nemo]

Great Ed, I will keep ma eyes open!!!!!

[EdF]

IMCG .47/.52 First Quarter 2005:

Intelligent Motor Cars Group Announces 7-for-1 Forward Split
Monday December 13, 5:28 pm ET


FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Dec. 13, 2004--Intelligent Motor Cars Group Inc. (OTCBB:IMCG - News), today announced that, through a board resolution on 12-9-04, its Board of Directors has declared a 7-for-1 stock split in the form of a common stock dividend to shareholders of record. As a result, shareholders of record will see seven additional shares for each share held as of the close of business on record date. The effective date will sometime during 1st quarter 2005, with the actual date to be announced after 1st of year.
Mike Magolnick, IMC's chief operating officer, stated, "We are delighted to reward our shareholders for their investment with this stock dividend. The decision was driven by several factors, including our confidence in the Company's improving fundamentals and future opportunities, as well as an indication to our shareholders and interested investors that we consider the market prospects for the Company to be excellent."

About Intelligent Motor Cars Group Inc.

Intelligent Motor Cars Group Inc., through its wholly owned subsidiary, Intelligent Motor Cars Inc. d/b/a Sun Auto Sales and Leasing, is a diverse South Florida car company, which provides, among other services, sales, service, reconditioning and financing. In addition to retail sales, IMCG is also engaged in wholesale, auction and Internet programs to market and sell vehicles to the financially challenged consumer market.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Intelligent Motor Cars Group Inc. ("the Company"), or automobile related industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements, including that the Company's current revenue levels are not necessarily indicative of its future revenue levels or future financial performance. The Company's future operating results are dependent upon many factors, including but not limited to: (i) whether the Company is able to obtain sufficient funding to fund its expansion plans; (ii) whether the Company is able to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments in the automobile industry; (iv) federal, state and local regulations pertaining to health and environmental quality standards; licensing/registration; financing; consumer protection; and safety; (v) the Company's ability to collect on receivables from high risk credit clients; (vi) the Company's ability to efficiently price and negotiate acquisitions on a favorable basis; (vii) whether the Company efficiently integrates the operations of other automobile dealerships it may acquire; and (viii) any negative economic conditions that would negatively affect the Company's business and expansion plans. Further information regarding the Company's business and its financial results may be obtained from the Company's periodic and other filings with the Securities and Exchange Commission which are available for review at www.sec.gov under "Search for Company Filings."



--------------------------------------------------------------------------------
Contact:
Intelligent Motor Cars Group Inc., Fort Lauderdale
Brian Heckathorne, 713-297-8886

[EdF]

WPCS .39/.40 March 15 2005(approx):

WPCS Reports Record Revenue For 2nd Quarter
Wednesday December 15, 9:52 am ET


EXTON, Pa., Dec. 15 /PRNewswire-FirstCall/ -- WPCS International Incorporated (OTC Bulletin Board: WPCS - News) has reported its financial results for the FY2005 second quarter ended October 31, 2004. For the second quarter of FY2005, WPCS reported record revenue of approximately $10.3 million compared to $6.2 million for the same period a year ago which represents an increase of 65%. In regards to the increase in reported quarterly revenue, $2.2 million was attributed to organic growth and the balance from past acquisitions. For the six months of FY2005 ended October 31, 2004, WPCS reported total revenue of approximately $17.6 million compared to $9.3 million for the same period a year ago which represents an increase of 89%. In regards to reported revenue for the six months ended October 31, 2004, $4.2 million was attributed to organic growth and the balance from past acquisitions.
For the second quarter of FY2005, the reported net income was $31,000 or $0.00 per share, which includes income taxes of $5,000 and depreciation and amortization of $125,000. For the same period last year, the reported net income was $11,000 or $0.00 per share, which included income taxes of $50,000 and depreciation and amortization of $91,000. For the six months of FY2005, the reported net income was $108,000 or $0.00 per share, which includes income taxes of $72,000 and depreciation and amortization of $247,000. For the same period last year, the reported net loss was $112,000 or $0.01 per share, which included income taxes of $91,000 and depreciation and amortization of $154,000.

Andrew Hidalgo, CEO of WPCS International Incorporated, commented: "We are pleased to report record revenue in our second quarter. In addition, this revenue generation does not include the contributions to be made from our recently announced acquisition, Quality Communications, which was acquired on November 24, 2004. The new acquisition will contribute both revenue and earnings in the third and fourth quarters of our current fiscal year, which will enhance our financial performance. WPCS is continuing to create operational efficiencies with the assimilation of subsidiaries and our primary focus is to improve earnings. In the second quarter, there was an increase in costs incurred on certain contracts that have since been completed. Other than the increase in costs on these projects, WPCS had a productive second quarter announcing $9.3 million in new major contracts. The current backlog is $21 million, which we expect to recognize over the next eight months. Also, for projects pending, the company has approximately $40 million of submitted bids. The business climate remains favorable for WPCS. With the addition of our new subsidiary Quality Communications and with our growing backlog and bid activity, we anticipate a strong FY2005 third and fourth quarter."

About WPCS International Incorporated:

WPCS International Incorporated is an engineering company that focuses on the implementation requirements of wireless technology and specialty communications systems. The company provides a range of services including site design, product integration, security, structured cabling, construction and project management. The company has an extensive customer base that includes many major corporations, government entities and educational institutions. For more information, please visit our website at http://www.wpcs.com.

Statements about the company's future expectations, including future revenue and earnings and all other statements in this press release, other than historical facts, are "forward-looking" statements and are made pursuant to safe harbor provisions of the Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time. The company's actual results could differ materially from expected results. In reflecting subsequent events or circumstances, the company undertakes no obligation to update forward-looking statements.

Contact:
Carol Lindley / Investor Relations
WPCS International Incorporated
610-903-0400 x-100
[e-mail]




--------------------------------------------------------------------------------
Source: WPCS International Incorporated

[EdF]

MXLK 3.85/4.40 December 2004

Particle Drilling Technologies Inc. Appoints New President and Chief Executive Officer

HOUSTON--(BUSINESS WIRE)--Dec. 2, 2004--Particle Drilling Technologies Inc. ("Particle Drilling" or "PDTI"), a developer of patented Particle Impact Drilling ("PID") technology for use in oil and gas exploration, announced today that it's Board of Directors has appointed John D. Schiller, Jr. as interim president and chief executive officer. Mr. Schiller previously served as an independent director on PDTI's Board. Simultaneously, Mr. Ken Lesuer who currently serves as vice chairman, will assume the role of chairman of PDTI. Prentis B. Tomlinson, one of PDTI's founders resigned as president, chief executive and chairman, but will continue to serve as a director.


With these management changes, PDTI believes it has an outstanding team of energy professionals in place to complete the commercialization of its PID technology. John Schiller has over 23 years of experience in the energy industry, including his role as vice president, Exploration and Production for Devon Energy following the $5.3 billion merger of Ocean Energy with Devon Energy Corporation (NYSE:DVN)(TSE:NSX) in 2003. Prior to the Devon merger John was executive vice president of Exploration and Production for Ocean Energy. John's primary objective will be to complete the commercialization of the PID system and to recruit and hire a seasoned oilfield service company executive capable of building PDTI into an international oilfield service and technology company.

John Schiller stated, "I have evaluated the PID system, the existing management team and the market and I believe PDTI has the opportunity to introduce a drilling technology capable of generating tremendous savings to the upstream E&P industry. The technology is well protected from an intellectual property standpoint and I look forward to bringing such a valuable technology into the market."

Prentis Tomlinson added, "As an entrepreneur I have started many energy-related companies over the years, and I believe this is the appropriate time to build on our management team in order to take PDTI to the next level. Particle Drilling has an outstanding market opportunity and I believe that this management team will be well positioned to deliver this technology to an industry that is searching for new efficiencies to lower the cost of finding and replacing reserves."

PDTI has previously announced its intention to merge with MedXlink (OTC Bulletin Board: MXLK.OB) and anticipates this merger will close before the end of the year.

The PID system is designed to substantially increase the rate of penetration in drilling for oil and gas, especially when drilling through hard rock and other difficult-to-drill formations. The PID process is a fully closed loop system where steel shot particles are injected into the drilling mud. The process is operated by hydraulic energy available under normal rig pump pressures, and the particles mixed with drilling fluid are accelerated through the nozzles in a specially designed drill bit. Each particle is driven into the rock formation at a velocity that delivers forces many times greater than the compression strength of the rock, even in formations that exist at elevated hardness and stress. It is anticipated that this system will dramatically accelerate the drilling process thereby improving economics of drilling and development plays. The PID system will be provided to the oil and gas exploration industry as a drilling service and is designed to work seamlessly with conventional drilling rigs and related equipment. This technology has been substantially developed and is being prepared for additional testing and commercial deployment.

Particle Drilling is headquartered in Houston. For further information, please contact J. Chris Boswell or Thomas E. Hardisty at the Company at 713-223-3031.

This news release contains forward-looking statements, including but not limited to, those that refer to the Company's plans for future securities listings, or future development plans or operating results. Actual results could differ materially from those anticipated due to risk factors that include, but are not limited to, speculative nature of oil and gas operations, speculative revenues from production, inadequate capital, adverse government regulations and/or other risk factors inherent in the oil and gas drilling, development and production sector.

NOTE: OS 2.5mil

[EdF]

TEQI 3.00/4.00 Week of 20 Dec 04:

Thomas Equipment, Inc. Announces Agreement in Principal to Acquire Pneutech Inc.
Pneutech Inc. to Become Wholly Owned Subsidiary of Thomas Equipment, Inc.
CHICAGO, IL -- (MARKET WIRE) -- 12/16/2004 -- David Marks, Chairman, Thomas Equipment, Inc., ("Thomas") (OTC BB: TEQI) announced today that Thomas reached an agreement in principal with Pneutech Inc. ("Pneutech") to acquire one hundred percent of its outstanding stock in a stock for stock tax free acquisition. Both companies expect a definitive agreement to be signed within the next week. Execution of a definitive agreement was approved by Thomas' Board of Directors; shareholders representing seventy eight percent of Pneutech have already approved the transaction.

Thomas is a leading global manufacturer of a full line of skid steer and mini skid steer loaders as well as attachments, mobile screening plants and six models of mini excavators. Thomas distributes its products through a worldwide network of distributors and wholesalers. In addition to its industrial and construction products it manufactures a complete line of potato harvesting and handling equipment.

Pneutech is a manufacturer of hydraulic systems and is a strategic supplier to Thomas. In the fiscal year ending October 31, 2004, Pneutech had revenue of approximately C$65,000,000. In addition, the current directors of Thomas will assume similar positions with Pneutech. The definitive agreement is subject to usual and customary commercial conditions including the approval of TEQI's lenders.

"The Pneutech acquisition is a key element in my overall strategy of building synergistic businesses with revolutionary technology." said Clifford Rhee, President and Director of Thomas. "We are now poised for continued expansion, both through acquisitions and via organic growth. Our mission is to make Thomas a leading international manufacturer in all of its product lines." Mr. Rhee and Mr. Kent own approximately 78% of the common shares of Pneutech.

TEQI Chairman David M. Marks stated: "This acquisition is integral to our overall acquisition strategy in this space. Cliff and I are confident that we will create tremendous shareholder value, as we continue to build the Thomas business." Thomas' counsel, Sichenzia Ross Friedman Ference LLP, http://www.srff.com/, represented it in the transaction.

About Thomas Equipment Inc. ("TEQI"): Thomas Equipment Inc., www.thomasequipment.net and www.thomasloaders.com, manufactures and distributes through a worldwide network of dealers and distributors a full line of skid steer and mini skid steer loaders as well as attachments, mobile screening plants and six models of mini excavators. In addition to its industrial and construction products it manufactures a complete line of potato harvesting and handling equipment.

Safe Harbor Statement Under the Private Securities Litigation Act of 1995 -- With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of either TEQI or CG could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rate and unanticipated events such as terrorist activities. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors see the risk factors associated with our Company, review our SEC filings.






--------------------------------------------------------------------------------


Contact:

New-School Communications, LLC
Blois Olson
651-221-1999
651-276-1678
www.new-school.com


SOURCE: Thomas Equipment Inc.

[EdF]

ADIY 4.96/5.05 January 2005:

(BSNS WIRE) American Dairy's New Processing Plant Nearing Completion

Business Editors
HEILONJIANG PROVINCE, China--(BUSINESS WIRE)--ADIY--
American Dairy, Inc. (OTCBB:ADIY), one of the leading
producers and distributors of milk powder and soy bean products in
China, announces that construction of the new 10 acre milk processing
plant in Kedong County, Heilongjang Province, China is near
completion.
Leng You-Bin, ADIY's chairman and CEO states, "this $14 million
plant will be the most modern and efficient milk processing plant in
China."
The new $4 million construction features an 183,000 square foot
workshop and an 8,600 square foot office building. $10 million of
processing equipment imported from Denmark and Belgium is expected to
arrive September 2004.
"Operations will commence January 2005 with production
capabilities of 300 tons per day," Mr. Leng announced, "American
Dairy's production will triple from the current 150 tons per day."
According to China's Growing Thirst for Dairy by Harry Baumes,
"China's dairy sector is one that should benefit from strong income
growth and its large market size (population: 1.3 billion). In recent
years, China's per capita consumption of dairy products has grown
dramatically (per capita milk consumption: 6.3 kilos (1998) to an
estimated 30 kilos by 2015)(1), and the country's domestic producers
have been unable to keep pace with the growing demand for dairy
products."(2)

Certain of the statements made herein constitute forward-looking
statements that involve risks and uncertainties. In such instances,
actual results could differ materially as a result of a variety of
factors including the risks associated with the effect of changing
economic conditions at home and abroad, variations in cash flow,
reliance on collaborative retail partners, and on new product
development, variations in new product and service development, risks
associated with rapid technological change, and potential of
introduced or undetected flaws and defects in products and services
and other risk factors detailed in forms filed with the Securities and
Exchange Commission from time to time.